Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
Authors
Keywords
-
Journal
OncoImmunology
Volume 5, Issue 6, Pages e1164919
Publisher
Informa UK Limited
Online
2016-03-29
DOI
10.1080/2162402x.2016.1164919
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HDAC inhibitors and immunotherapy; a double edged sword?
- (2015) Michiel Kroesen et al. Oncotarget
- Key role for myeloid cells: Phase II results of anti-GD2antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma
- (2014) Nai-Kong V. Cheung et al. INTERNATIONAL JOURNAL OF CANCER
- Macrophages eliminate circulating tumor cells after monoclonal antibody therapy
- (2014) Nuray Gül et al. JOURNAL OF CLINICAL INVESTIGATION
- Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2014) J.-I. Youn et al. JOURNAL OF IMMUNOLOGY
- The cellular and molecular origin of tumor-associated macrophages
- (2014) R. A. Franklin et al. SCIENCE
- Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma
- (2013) Lena-Maria Carlson et al. CARCINOGENESIS
- Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells
- (2013) G. Santilli et al. CLINICAL CANCER RESEARCH
- A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma
- (2013) Michiel Kroesen et al. INTERNATIONAL JOURNAL OF CANCER
- Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
- (2013) Branka Petricevic et al. Journal of Translational Medicine
- Myeloid cells as effector cells for monoclonal antibody therapy of cancer
- (2013) Rens Braster et al. METHODS
- HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
- (2013) Byram W Bridle et al. MOLECULAR THERAPY
- MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma
- (2013) Marco Lodrini et al. NUCLEIC ACIDS RESEARCH
- HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
- (2013) J E Bolden et al. Cell Death & Disease
- The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
- (2012) Dennis Lindau et al. IMMUNOLOGY
- Immunocombination therapy for high-risk neuroblastoma
- (2012) Michiel Kroesen et al. Immunotherapy
- Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment
- (2012) Nidale Tarek et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma
- (2012) Shahab Asgharzadeh et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function
- (2012) K. D. Grugan et al. JOURNAL OF IMMUNOLOGY
- Trial Watch: Monoclonal antibodies in cancer therapy
- (2012) Lorenzo Galluzzi et al. OncoImmunology
- Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
- (2011) Thorsten Simon et al. BMC CANCER
- Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy
- (2011) P. Hubert et al. CANCER RESEARCH
- HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
- (2011) Omar Khan et al. IMMUNOLOGY AND CELL BIOLOGY
- Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
- (2011) Tangying Lu et al. JOURNAL OF CLINICAL INVESTIGATION
- Histone acetylation-mediated glycosyltransferase gene regulation in mouse brain during development
- (2011) Yusuke Suzuki et al. JOURNAL OF NEUROCHEMISTRY
- Preclinical Models for Neuroblastoma: Establishing a Baseline for Treatment
- (2011) Tal Teitz et al. PLoS One
- Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies
- (2011) A. J. Christiansen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer cells’ epigenetic composition and predisposition to histone deacetylase inhibitor sensitization
- (2011) Narasimharao Nalabothula et al. Epigenomics
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
- (2010) K. Movahedi et al. CANCER RESEARCH
- Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs
- (2010) Tatiana Akimova et al. CLINICAL IMMUNOLOGY
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
- (2010) Maryam Fouladi et al. JOURNAL OF CLINICAL ONCOLOGY
- CD49d Is a New Marker for Distinct Myeloid-Derived Suppressor Cell Subpopulations in Mice
- (2010) L. A. Haile et al. JOURNAL OF IMMUNOLOGY
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of MYCNexpression in human neuroblastoma cells
- (2009) Joannes FM Jacobs et al. BMC CANCER
- Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
- (2009) D. D. Vo et al. CANCER RESEARCH
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
- (2009) Katherine K. Matthay et al. JOURNAL OF CLINICAL ONCOLOGY
- M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
- (2009) M. Leidi et al. JOURNAL OF IMMUNOLOGY
- Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity
- (2008) K. Movahedi et al. BLOOD
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein
- (2008) Pingyan Cheng et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6
- (2008) Alan P. Kozikowski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis21
- (2008) Keiko Furukawa et al. JOURNAL OF NEUROCHEMISTRY
- Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells
- (2008) Annick Muhlethaler-Mottet et al. Molecular Cancer
- Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation
- (2008) C. K. Hahn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells
- (2007) F Condorelli et al. BRITISH JOURNAL OF PHARMACOLOGY
- High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
- (2007) Danielle Canioni et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started